New treatments for lung infections caused by Mycobacteroides abscessus
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection
This study is looking at new ways to treat tough lung infections caused by a bacteria called Mycobacteroides abscessus, especially for people with cystic fibrosis, bronchiectasis, or COPD, by testing combinations of antibiotics that might work better together while using lower doses to reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10904743 on NIH RePORTER |
What this research studies
This research focuses on developing new antibiotic regimens to effectively treat chronic lung infections caused by the bacterium Mycobacteroides abscessus, particularly in patients with conditions like cystic fibrosis, bronchiectasis, and COPD. The study aims to explore the use of paired combinations of β-lactam antibiotics, which have shown promise in laboratory settings for their ability to work synergistically against this drug-resistant bacterium. By testing these combinations at lower doses, the research seeks to improve treatment efficacy while minimizing side effects. The ultimate goal is to provide a more effective and safer treatment option for patients suffering from these challenging infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic lung diseases such as cystic fibrosis, bronchiectasis, or COPD who are infected with Mycobacteroides abscessus.
Not a fit: Patients without chronic lung conditions or those not infected with Mycobacteroides abscessus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with chronic lung infections caused by Mycobacteroides abscessus.
How similar studies have performed: Previous research has shown promise in using combination antibiotic therapies for treating resistant bacterial infections, suggesting potential success for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Lamichhane, Gyanu — Johns Hopkins University
- Study coordinator: Lamichhane, Gyanu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.